- Home
- XMTR vs CGON Comparison
XMTR vs CGON Comparison
Compare XMTR & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XMTR
- CGON
- Stock Information
- Founded
- XMTR 2013
- CGON 2010
- Country
- XMTR United States
- CGON United States
- Employees
- XMTR N/A
- CGON N/A
- Industry
- XMTR Industrial Machinery/Components
- CGON
- Sector
- XMTR Technology
- CGON
- Exchange
- XMTR Nasdaq
- CGON NYSE
- Market Cap
- XMTR 1.1B
- CGON 1.3B
- IPO Year
- XMTR 2021
- CGON 2024
- Fundamental
- Price
- XMTR $32.63
- CGON $26.26
- Analyst Decision
- XMTR Buy
- CGON Strong Buy
- Analyst Count
- XMTR 11
- CGON 10
- Target Price
- XMTR $34.09
- CGON $64.00
- AVG Volume (30 Days)
- XMTR 640.8K
- CGON 1.4M
- Earning Date
- XMTR 05-06-2025
- CGON 05-13-2025
- Dividend Yield
- XMTR N/A
- CGON N/A
- EPS Growth
- XMTR N/A
- CGON N/A
- EPS
- XMTR N/A
- CGON N/A
- Revenue
- XMTR $573,810,000.00
- CGON $662,000.00
- Revenue This Year
- XMTR $21.56
- CGON N/A
- Revenue Next Year
- XMTR $17.54
- CGON $12,387.03
- P/E Ratio
- XMTR N/A
- CGON N/A
- Revenue Growth
- XMTR 19.35
- CGON 224.51
- 52 Week Low
- XMTR $11.08
- CGON $14.80
- 52 Week High
- XMTR $45.33
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- XMTR 56.76
- CGON 56.19
- Support Level
- XMTR $32.28
- CGON $24.95
- Resistance Level
- XMTR $35.14
- CGON $26.60
- Average True Range (ATR)
- XMTR 1.74
- CGON 1.41
- MACD
- XMTR -0.29
- CGON 0.01
- Stochastic Oscillator
- XMTR 44.83
- CGON 64.14
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.